中樞神經系統領域的合作與授權協議（2020-2026）

中樞神經系統（CNS）領域交易的權威基準。

中樞神經系統 (CNS) 領域的合作涵蓋了廣泛的交易結構，無論適應症、治療方法或開發階段如何，都反映了該領域的科學複雜性和風險狀況。

本報告對中樞神經系統領域的 900 多項合作與許可協議進行了全面系統的分析，清楚地展示了夥伴關係在整個市場中的設計、談判和執行方式，並提供了實證支持。

清楚了解市場標準

本報告將幫助您準確了解 CNS 交易的實際構成，並使您能夠：

• 自信地對標類似交易
• 對相關交易中的預付款、里程碑付款和特許權使用費結構進行詳細分析。
• 設定切合實際的市場參數
• 深入了解交易條款如何因階段、資產類型和合作夥伴情況而異。
• 支持實證評估和結構性決策
• 我們將根據實際交易數據進行內部討論，而不是根據假設。
• 了解主要企業如何處理交易
• 在廣泛的治療領域中，可視化合作夥伴的行為和重複交易模式。
• 全面了解交易結構和執行情況
• 本報告超越了表面的交易數據，提供了對底層合約文件的訪問，從而可以詳細了解實際合約是如何構建的。

這包括：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和支付觸發機制
• 關鍵合約條款和保障措施
• 這種程度的透明度對於了解 CNS夥伴關係中價值、風險和控制權的分配方式至關重要，尤其是在發展不確定性較高的地區。
• 專為實際業務發展和策略制定而設計。

本報告主要廣泛用於以下用途：

• 建置和基準測試實際交易
• 在清晰的市場環境下準備談判
• 夥伴關係機會及交易對象評估
• 支援穩健且引人注目的數據驅動型內部策略
• 內容
• 超過900項中樞神經系統（CNS）合作及授權協議
• 財務條款，包括預付款、里程碑付款和版稅（如有揭露）。
• 可全文搜尋的合約目錄（依公司、治療領域及技術分類）
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 分析交易趨勢、重大交易和活躍的交易商。
• 關於中樞神經系統領域交易的可靠、基於證據的參考資料。
• 本報告結合全面的交易覆蓋範圍和合約層面的見解，為如何在CNS領域建立、談判和評估夥伴關係提供了可靠的、基於證據的參考資料。

目錄

摘要整理

第1章：引言

第2章：中樞神經系統交易趨勢

• 介紹
• 中樞神經系統已經協同工作多年了。
• 中樞神經系統相關合作項目（依交易類型分類）
• 中樞神經系統相關合作關係（按產業分類）
• 中樞神經系統相關協作（依發育階段）
• 中樞神經系統相關合作關係（依技術類型分類）
• 中樞神經系統相關協作（按治療適應症）

第3章 中樞神經夥伴關係中的財務術語

• 介紹
• 中樞神經系統夥伴關係的財務條款將予以揭露。
• 中樞神經系統夥伴關係的關鍵價值
• 中樞神經系統預付款
• 與中樞神經系統相關的交易的里程碑付款
• 中樞神經系統的專利費率

第4章：中樞神經系統相關交易的主要交易與相關人員

• 介紹
• 與中樞神經系統合作最活躍的公司
• 中樞神經系統中最活躍的相關人員名單
• 高價值中樞神經相關交易

第5章：中樞神經系統合約文件清單

• 介紹
• 與中樞神經系統相關的合作協議（如有協議）

第6章：中樞神經系統治療標靶交易

• 介紹
• 基於中樞神經系統治療標靶的交易
• 交易目錄
• 交易目錄 - 公司（AZ）中樞神經系統相關交易
• 交易目錄 - 中樞神經系統相關交易（依技術類型分類）
• 交易類型的定義
• 關於這家研究公司
• Current Partnering
• 目前合約
• 理想合作夥伴最新報告的標題

The definitive benchmark for central nervous system dealmaking

Central nervous system (CNS) partnering spans a wide range of deal structures across indications, modalities, and stages of development, reflecting the scientific complexity and risk profile of the space.

This report provides a comprehensive and structured analysis of 900+ CNS collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how CNS deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by stage, asset type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a highly heterogeneous therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within CNS partnerships, particularly in areas with higher development uncertainty.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 900+ CNS collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and technology)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for CNS dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how CNS partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in central nervous system dealmaking

• 2.1. Introduction
• 2.2. Central nervous system partnering over the years
• 2.3. Central nervous system partnering by deal type
• 2.4. Central nervous system partnering by industry sector
• 2.5. Central nervous system partnering by stage of development
• 2.6. Central nervous system partnering by technology type
• 2.7. Central nervous system partnering by therapeutic indication

Chapter 3 - Financial deal terms for central nervous system partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for central nervous system partnering
• 3.3. Central nervous system partnering headline values
• 3.4. Central nervous system deal upfront payments
• 3.5. Central nervous system deal milestone payments
• 3.6. Central nervous system royalty rates

Chapter 4 - Leading central nervous system deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in central nervous system partnering
• 4.3. List of most active dealmakers in central nervous system
• 4.4. Top central nervous system deals by value

Chapter 5 - Central nervous system contract document directory

• 5.1. Introduction
• 5.2. Central nervous system partnering deals where contract document available

Chapter 6 - Central nervous system dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by central nervous system therapeutic target
• Deal Directory
• Deal Directory - Central nervous system deals by company A-Z
• Deal Directory - Central nervous system deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Central nervous system partnering since 2020
• Figure 2: Central nervous system partnering by deal type since 2020
• Figure 3: Central nervous system partnering by industry sector since 2020
• Figure 4: Central nervous system partnering by stage of development since 2020
• Figure 5: Central nervous system partnering by technology type since 2020
• Figure 6: Central nervous system partnering by indication since 2020
• Figure 7: Central nervous system deals with a headline value
• Figure 8: Central nervous system deals with upfront payment values
• Figure 9: Central nervous system deals with milestone payment
• Figure 10: Central nervous system deals with royalty rates
• Figure 11: Active central nervous system dealmaking activity since 2020
• Figure 12: Top central nervous system deals by value since 2020